Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Licensing agreement signed for OxSODrol

Sep. 5, 1997

Merck's asthma treatment receives first approvals

Sep. 4, 1997

Celltech prepares PDE IV inhibitors

Sep. 4, 1997

Sepracor's levalbuterol NDA accepted by FDA

Sep. 4, 1997

LT antagonist/antihistamine combination highly effective against EAR/LAR

Sep. 3, 1997

ET antagonists for asthma

Sep. 2, 1997

Anti-IgE antibody inhibits allergen-induced EAR

Sep. 2, 1997

North American clinical trials with LiquiVent to be reinitiated

Sep. 1, 1997

P&U cephem derivatives for inhibiting HLE

Aug. 29, 1997

FDA approves Hi-Tech's generic promethazine/codeine syrup

Aug. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...